The Company acquired Tiziana Pharma Limited (“TPL”) via a reverse takeover (as defined in the AIM Rules). The acquisition completed on 24 April 2014. TPL was formed in November 2013 as a vehicle to acquire and exploit certain intellectual property in biotechnology. Its mission is to discover and develop novel molecules that impact human disease in the area of oncology, with a particular focus on metastatic cancers. The first of TPL’s programmes seeks to develop a drug for application in the therapeutic area of metastatic breast cancer.